Trial · NCT07891481
Effects of Different Kinesio Taping Methods in Subacromial Impingement Syndrome
NCT07891481, Not applicable, Not yet recruiting, Pamukkale University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effects of Different Kinesio Taping Methods in Subacromial Impingement Syndrome. Trials, record NCT07891481. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07891481
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effects of Different Kinesio Taping Methods in Subacromial Impingement Syndrome
- NCT number
- NCT07891481
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 72 participants, estimated
- Lead sponsor
- Pamukkale University
- Conditions
- Subacromial Impingement Syndrome
- Interventions
- Conventional Kinesio Taping, Scapular Kinesio Taping, Therapeutic Exercise Program
- First posted
- 2026-10-23
- Last updated
- 2026-10-23
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Acromiohumeral Distance (AHD) Measured by Ultrasonography | Baseline (before treatment) and week 8 (after completion of treatment). | Acromiohumeral distance (AHD) will be measured using a Clarius L7 HD linear ultrasound scanner at 0° and 60° of shoulder abduction. Participants will be seated upright. At 0°, the arm will rest beside the body with the elbow extended. At 60°, the arm will be abducted with the elbow extended and palm facing downward. The abduction angle will be verified using a Baseline Digital Inclinometer. The ultrasound probe will be positioned at the lateral acromion, aligned with the longitudinal axis of the humerus. AHD will be defined as the shortest distance between the inferior border of the acromion and the humeral head. Three measurements will be obtained at each position, and the mean value in millimeters will be used for analysis. Changes from baseline to week 8 will be compared between groups. |
| Secondary | Change in Shoulder Pain Intensity Assessed by Visual Analog Scale (VAS) | Baseline (before treatment) and week 8 (after completion of treatment). | Shoulder pain intensity will be assessed using a 10-cm Visual Analog Scale (VAS). Participants will separately rate their current pain at rest, pain experienced during activity in the previous 24 hours, and shoulder pain experienced during the previous night. The scale ranges from 0 (no pain) to 10 (worst imaginable pain). Higher scores indicate greater pain intensity. Changes in pain scores from baseline to week 8 will be evaluated. |
| Secondary | Change in Shoulder Pain and Disability Index (SPADI) Score | Baseline (before treatment) and week 8 (after completion of treatment). | Shoulder pain and functional disability will be assessed using the Shoulder Pain and Disability Index (SPADI). The questionnaire consists of 13 items divided into two subscales: pain (5 items) and disability (8 items). Each item is scored from 0 to 10. Pain and disability subscale scores are converted to percentages ranging from 0 to 100, and the total SPADI score is calculated as the mean of the two subscale scores. Higher scores indicate greater pain and functional disability. Changes in total SPADI scores from baseline to week 8 will be evaluated. |
| Secondary | Change in Western Ontario Rotator Cuff Index (WORC) Score | Baseline (before treatment) and week 8 (after completion of treatment). | Rotator cuff disease-specific health-related quality of life will be assessed using the Western Ontario Rotator Cuff Index (WORC). The questionnaire consists of 21 items across five domains: physical symptoms, sports and recreation, work, lifestyle, and emotions. Each item is scored on a 100-mm Visual Analog Scale. The total score ranges from 0 to 2100, with higher scores indicating greater impairment and poorer health-related quality of life. Changes in total WORC scores from baseline to week 8 will be evaluated. |
| Secondary | Change in Shoulder Joint Position Error (JPE) | Baseline (before treatment) and week 8 (after completion of treatment). | Shoulder proprioception will be assessed using an active joint repositioning test with a Baseline Digital Inclinometer. Measurements will be performed during shoulder flexion and abduction at target angles of 60° and 120°. Participants will be seated with their eyes closed. The examiner will position the arm at the target angle for 5 seconds, after which participants will actively reproduce the position without visual feedback. Joint Position Error (JPE) will be calculated as the absolute difference in degrees between the target and reproduced angles. Three trials will be performed for each target angle, and the mean absolute error will be recorded. Lower JPE values indicate better proprioceptive accuracy. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers5
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07891481
GET https://conductscience.org/api/trials/v1/NCT07891481/registered